Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 14Phase 1 13Phase 3 6Phase 4 3Phase NA 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hodgkin Disease 2Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1

Interventions

Cyclophosphamide 16fludarabine phosphate 13Peripheral Blood Stem Cell Transplantation 13Whole-Body Irradiation 10Cyclosporine 10Antilymphocyte Serum 9Melphalan 8Busulfan 8Mycophenolic Acid 7Filgrastim 6fludarabine 5Radiotherapy 5Methotrexate 5Etoposide 5Psychiatric Rehabilitation 4Methylprednisolone 4Cytarabine 4Carmustine 4Blood Specimen Collection 4thymoglobulin 3Therapeutics 3Rituximab 3Flow Cytometry 3Aprepitant 3Analgesia 3Tacrolimus 2Stem Cell Transplantation 2Proton Therapy 2Polymerase Chain Reaction 2Ondansetron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Hodgkin Disease × Brentuximab Vedotin × Clear all
NCT01868451 2026-06-04

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase NA Completed
118 enrolled
Lymphoid

Hodgkin Disease

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
41 enrolled 14 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡